95 related articles for article (PubMed ID: 9549923)
21. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
[TBL] [Abstract][Full Text] [Related]
22. Fludarabine and cytarabine as continuous sequential infusion for elderly patients with acute myeloid leukemia.
Ferrara F; D'Arco AM; De Simone M; Mele G; Califano C; Pocali B; Danise P; Palmieri S
Haematologica; 2005 Jun; 90(6):776-84. PubMed ID: 15951290
[TBL] [Abstract][Full Text] [Related]
23. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
Hołowiecki J; Grosicki S; Kyrcz-Krzemien S; Skotnicki AB; Piatkowska-Jakubas B; Warzocha K; Seferynska I; Zdziarska B
Ann Hematol; 2008 May; 87(5):361-7. PubMed ID: 18074133
[TBL] [Abstract][Full Text] [Related]
24. Survival of elderly patients with acute myeloid leukemia.
Pulsoni A; Pagano L; Latagliata R; Casini M; Cerri R; Crugnola M; De Paoli L; Di Bona E; Invernizzi R; Marmont F; Petti MC; Rigolin G; Ronco F; Spadano A; Tosti ME; Visani G; Mele A; Mandelli F
Haematologica; 2004 Mar; 89(3):296-302. PubMed ID: 15020267
[TBL] [Abstract][Full Text] [Related]
25. Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia.
Roboz GJ; Ritchie EK; Curcio T; Provenzano J; Carlin R; Samuel M; Wittenberg B; Mazumdar M; Christos PJ; Mathew S; Allen-Bard S; Feldman EJ
Cancer; 2008 Nov; 113(9):2504-11. PubMed ID: 18825661
[TBL] [Abstract][Full Text] [Related]
26. Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia.
Clavio M; Venturino C; Pierri I; Garrone A; Miglino M; Canepa L; Balleari E; Balocco M; Michelis GL; Ballerini F; Gobbi M
Ann Hematol; 2004 Nov; 83(11):696-703. PubMed ID: 15322763
[TBL] [Abstract][Full Text] [Related]
27. [Long-term results of the UHKT-911 study of adult patients under 65 years of age with de novo acute myeloid leukemias without favorable karyotypes].
Lemez P; Vítek A; Michalová K; Zemanová Z; Lukásová M
Vnitr Lek; 2003 Mar; 49(3):174-80. PubMed ID: 12728590
[TBL] [Abstract][Full Text] [Related]
28. Addition of cyclosporin-A to chemotherapy in secondary (post-MDS) AML in the elderly. A multicenter randomized trial of the Leukemia Working Group of the Hellenic Society of Hematology.
Matsouka P; Pagoni M; Zikos P; Giannakoulas N; Apostolidis I; Asprogeraka T; Arvanitopoulou E; Spanoudakis E; Kotsianidis I; Tsatalas K; Papaioannou M; Marinakis T; Skandali A; Viniou N; Yataganas X; Bakiri M
Ann Hematol; 2006 Apr; 85(4):250-6. PubMed ID: 16416114
[TBL] [Abstract][Full Text] [Related]
29. The treatment of acute myeloid leukemia with mitoxantrone, etoposide and low-dose cytarabine in elderly patients - a report of Polish Acute Leukemia Group (PALG) phase II study.
Wrzesien-Kus A; Robak T; Jamroziak K; Wierzbowska A; Dmoszynska A; Adamczyk-Cioch M; Kuliczkowski K; Mazur G; Holowiecki J; Konopka L; Maj S; Marianska B; Zawilska K;
Neoplasma; 2002; 49(6):405-11. PubMed ID: 12584589
[TBL] [Abstract][Full Text] [Related]
30. Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup.
Prébet T; Boissel N; Reutenauer S; Thomas X; Delaunay J; Cahn JY; Pigneux A; Quesnel B; Witz F; Thépot S; Ugo V; Terre C; Recher C; Tavernier E; Hunault M; Esterni B; Castaigne S; Guilhot F; Dombret H; Vey N; ; ;
J Clin Oncol; 2009 Oct; 27(28):4747-53. PubMed ID: 19720919
[TBL] [Abstract][Full Text] [Related]
31. Long-term outcome of intensive chemotherapy for adults with de novo acute myeloid leukaemia (AML): the nationwide AML-92 study by the Finnish Leukaemia Group.
Koistinen P; Räty R; Itälä M; Jantunen E; Koivunen E; Nousiainen T; Pelliniemi TT; Remes K; Ruutu T; Savolainen ER; Siitonen T; Silvennoinen R; Volin L; Elonen E;
Eur J Haematol; 2007 Jun; 78(6):477-86. PubMed ID: 17391337
[TBL] [Abstract][Full Text] [Related]
32. Outcome of patients with acute myelogenous leukemia after second salvage therapy.
Giles F; O'Brien S; Cortes J; Verstovsek S; Bueso-Ramos C; Shan J; Pierce S; Garcia-Manero G; Keating M; Kantarjian H
Cancer; 2005 Aug; 104(3):547-54. PubMed ID: 15973664
[TBL] [Abstract][Full Text] [Related]
33. [Prognostic factor analysis of 77 old patients with acute myelogenous leukemia].
Shao B; Gao YR; Wang C; Yan SK; Cai Q; Jiang JL; Yang J; Bai HT; Zhao M; Zhao CX
Ai Zheng; 2006 Aug; 25(8):1007-12. PubMed ID: 16965684
[TBL] [Abstract][Full Text] [Related]
34. Acute myeloid leukemia in the elderly:--159 Nagoya case studies--Nagoya Cooperative Study Group for Elderly Leukemia.
Nagura E; Minami S; Nagata K; Morishita Y; Takeyama H; Sao H; Suzuki H; Naoe T; Yokomaku S; Mizuno H; Murase T; Hirabayashi N; Takeo T; Tanimoto M; Kawashima K; Saito H
Nagoya J Med Sci; 1999 Nov; 62(3-4):135-44. PubMed ID: 10689875
[TBL] [Abstract][Full Text] [Related]
35. Acute myeloid leukaemia (AML): treatment of the older patient.
Büchner T; Hiddemann W; Schoch C; Haferlach T; Sauerland MC; Heinecke A
Best Pract Res Clin Haematol; 2001 Mar; 14(1):139-51. PubMed ID: 11355928
[TBL] [Abstract][Full Text] [Related]
36. Maintenance therapy in childhood acute myeloid leukemia.
Perel Y; Auvrignon A; Leblanc T; Michel G; Vannier JP; Dalle JH; Gandemer V; Schmitt C; Mèchinaud F; Lamagnere JP; Piguet Ch; Couillaud G; Pautard B; Baruchel A; Leverger G; ;
Ann Hematol; 2004; 83 Suppl 1():S116-9. PubMed ID: 15124700
[TBL] [Abstract][Full Text] [Related]
37. A randomized trial of continuous infusion versus bolus mitoxantrone in combination with cytarabine in newly diagnosed patients with acute myeloblastic leukemia.
Koc Y; Oyan B; Kars A; Tekuzman G; Canpinar H; Kansu E
Hematol Oncol; 2004 Jun; 22(2):43-53. PubMed ID: 15386563
[TBL] [Abstract][Full Text] [Related]
38. The benefit of induction chemotherapy in patients age > or = 75 years.
Vey N; Coso D; Bardou VJ; Stoppa AM; Braud AC; Bouabdallah R; Sainty D; Mozziconacci MJ; Lafage M; Damaj G; Blaise D; Gastaut JA; Maraninchi D
Cancer; 2004 Jul; 101(2):325-31. PubMed ID: 15241830
[TBL] [Abstract][Full Text] [Related]
39. CD56 and PGP expression in acute myeloid leukemia: impact on clinical outcome.
Raspadori D; Damiani D; Michieli M; Stocchi R; Gentili S; Gozzetti A; Masolini P; Michelutti A; Geromin A; Fanin R; Lauria F
Haematologica; 2002 Nov; 87(11):1135-40. PubMed ID: 12414342
[TBL] [Abstract][Full Text] [Related]
40. Essential thrombocythemia and acute leukemia.
Ferrari D; Ticozzelli G; De Vizzi M; Corigliano P; De Vizzi G
Haematologica; 1993; 78(6):401-2. PubMed ID: 8175035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
